PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7617307-6 1995 IDO activity is increased in HIV-associated dementia and is thus likely to increase kynurenine pathway metabolites, such as 3-hydroxykynurenine and quinolinic acid, and elevated levels of these neurotoxins may contribute to the neuronal deficits underlying HIV-associated dementia. Quinolinic Acid 148-163 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-3 15961516-2 2005 IDO activity is linked with immunosuppression by its ability to inhibit lymphocyte proliferation, and with neurotoxicity through the generation of quinolinic acid and other toxins. Quinolinic Acid 147-162 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-3 15182307-2 2004 Indoleamine-2,3-dioxygenase (IDO) initiates the increased production of kynurenine pathway metabolites like quinolinic acid (QUIN). Quinolinic Acid 108-123 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-27 15182307-2 2004 Indoleamine-2,3-dioxygenase (IDO) initiates the increased production of kynurenine pathway metabolites like quinolinic acid (QUIN). Quinolinic Acid 108-123 indoleamine 2,3-dioxygenase 1 Homo sapiens 29-32 15182307-2 2004 Indoleamine-2,3-dioxygenase (IDO) initiates the increased production of kynurenine pathway metabolites like quinolinic acid (QUIN). Quinolinic Acid 125-129 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-27 15182307-2 2004 Indoleamine-2,3-dioxygenase (IDO) initiates the increased production of kynurenine pathway metabolites like quinolinic acid (QUIN). Quinolinic Acid 125-129 indoleamine 2,3-dioxygenase 1 Homo sapiens 29-32 14592780-4 2003 Recently, pro-inflammatory cytokines have been found to have profound effects on the metabolism of brain serotonin through the enzyme indoleamine-2,3-dioxygenase (IDO) that metabolizes the tryptophan, the precursor of 5-HT to neurodegenerative quinolinate and neuroprotective kynurenate. Quinolinic Acid 244-255 indoleamine 2,3-dioxygenase 1 Homo sapiens 134-161 14592780-4 2003 Recently, pro-inflammatory cytokines have been found to have profound effects on the metabolism of brain serotonin through the enzyme indoleamine-2,3-dioxygenase (IDO) that metabolizes the tryptophan, the precursor of 5-HT to neurodegenerative quinolinate and neuroprotective kynurenate. Quinolinic Acid 244-255 indoleamine 2,3-dioxygenase 1 Homo sapiens 163-166 12414962-2 2002 Indoleamine 2,3-dioxygenase (IDO), the first and rate-limiting enzyme in tryptophan catabolism in extrahepatic tissues, can lead to neurotoxicity through the generation of quinolinic acid and immunosuppression and can alter brain chemistry via depletion of tryptophan. Quinolinic Acid 172-187 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-27 12414962-2 2002 Indoleamine 2,3-dioxygenase (IDO), the first and rate-limiting enzyme in tryptophan catabolism in extrahepatic tissues, can lead to neurotoxicity through the generation of quinolinic acid and immunosuppression and can alter brain chemistry via depletion of tryptophan. Quinolinic Acid 172-187 indoleamine 2,3-dioxygenase 1 Homo sapiens 29-32 10834318-3 2000 IFN-gamma stimulates the enzyme indoleamine (2,3)-dioxygenase (IDO) converting tryptophan to the metabolite kynurenine which in macrophages is subsequently degraded to other, partly neurotoxic compounds like quinolinic acid, and finally to nicrotinamides. Quinolinic Acid 208-223 indoleamine 2,3-dioxygenase 1 Homo sapiens 63-66 15206722-6 2003 This quantitative difference in the ability to produce QUIN appears to be associated with a lower expression of 3 important enzymes of the KP in microglia: indoleamine 2,3-dioxygenase (IDO), kynureninase (KYNase) and kynurenine hydroxylase (KYN(OH)ase). Quinolinic Acid 55-59 indoleamine 2,3-dioxygenase 1 Homo sapiens 156-183 15206722-6 2003 This quantitative difference in the ability to produce QUIN appears to be associated with a lower expression of 3 important enzymes of the KP in microglia: indoleamine 2,3-dioxygenase (IDO), kynureninase (KYNase) and kynurenine hydroxylase (KYN(OH)ase). Quinolinic Acid 55-59 indoleamine 2,3-dioxygenase 1 Homo sapiens 185-188 27540379-8 2016 Similar to microglia and macrophages, these cells are highly responsive to IFN-gamma, which upregulates the expression of enzymes, including IDO-1, producing neurotoxic KP metabolites such as quinolinic acid. Quinolinic Acid 192-207 indoleamine 2,3-dioxygenase 1 Homo sapiens 141-146 34735466-3 2021 We aim to elucidate the distribution pattern of IDO-1+ macrophages/microglia in the human brain tissues, human glioblastoma, APP/PS1 mouse brains, and quinolinic acid model brains and explore the physiological and immunological roles of IDO-1+ macrophages/microglia. Quinolinic Acid 151-166 indoleamine 2,3-dioxygenase 1 Homo sapiens 48-53 31733567-2 2020 Indoleamine-2, 3-dioxygenase (IDO) initiates the increased production of kynurenine pathway (KP) metabolites quinolinic acid (QUIN), which has an excitotoxic effect for neurons. Quinolinic Acid 109-124 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-28 31733567-2 2020 Indoleamine-2, 3-dioxygenase (IDO) initiates the increased production of kynurenine pathway (KP) metabolites quinolinic acid (QUIN), which has an excitotoxic effect for neurons. Quinolinic Acid 109-124 indoleamine 2,3-dioxygenase 1 Homo sapiens 30-33 31733567-2 2020 Indoleamine-2, 3-dioxygenase (IDO) initiates the increased production of kynurenine pathway (KP) metabolites quinolinic acid (QUIN), which has an excitotoxic effect for neurons. Quinolinic Acid 126-130 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-28 31733567-2 2020 Indoleamine-2, 3-dioxygenase (IDO) initiates the increased production of kynurenine pathway (KP) metabolites quinolinic acid (QUIN), which has an excitotoxic effect for neurons. Quinolinic Acid 126-130 indoleamine 2,3-dioxygenase 1 Homo sapiens 30-33 29254065-2 2018 Indoleamine 2,3-dioxygenase (IDO) is the rate limiting enzyme which leads to neurotrophic [kynurenic acid (KA)] and neurotoxic [Quinolinic acid (QUIN)] branches. Quinolinic Acid 145-149 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-27 29254065-2 2018 Indoleamine 2,3-dioxygenase (IDO) is the rate limiting enzyme which leads to neurotrophic [kynurenic acid (KA)] and neurotoxic [Quinolinic acid (QUIN)] branches. Quinolinic Acid 145-149 indoleamine 2,3-dioxygenase 1 Homo sapiens 29-32 30430940-9 2018 Activated immune-inflammatory pathways induce indoleamine-2,3-dioxynease (IDO) and the tryptophan catabolite (TRYCAT) pathway thereby increasing tryptophan degradation and increasing the production of TRYCATs including kynurenine and quinolinic acid, which may create an overall anxiogenic effect. Quinolinic Acid 234-249 indoleamine 2,3-dioxygenase 1 Homo sapiens 46-72 30430940-9 2018 Activated immune-inflammatory pathways induce indoleamine-2,3-dioxynease (IDO) and the tryptophan catabolite (TRYCAT) pathway thereby increasing tryptophan degradation and increasing the production of TRYCATs including kynurenine and quinolinic acid, which may create an overall anxiogenic effect. Quinolinic Acid 234-249 indoleamine 2,3-dioxygenase 1 Homo sapiens 74-77 28529072-6 2017 Moreover, EPA and DHA also reversed the IL-1beta-induced increase in kynurenine, as well as mRNA levels of indolamine-2,3-dioxygenase (IDO); while DHA and sertraline reverted the IL-1beta-induced increase in quinolinic acid and mRNA levels of kynurenine 3-monooxygenase (KMO). Quinolinic Acid 208-223 indoleamine 2,3-dioxygenase 1 Homo sapiens 135-138 28077028-3 2017 Enhanced IDO expression leads to reduced tryptophan levels and increased levels of toxic metabolites, including quinolinic acid. Quinolinic Acid 112-127 indoleamine 2,3-dioxygenase 1 Homo sapiens 9-12 8293279-7 1993 Induction of spinal cord IDO (35.9-fold) accompanied smaller, but proportional increases in kynurenine-3-hydroxylase (2.4-fold) and kynureninase (2.3-fold) activities, which were correlated to CSF and tissue QUIN levels, as well as to measures of inflammatory lesions. Quinolinic Acid 208-212 indoleamine 2,3-dioxygenase 1 Homo sapiens 25-28 8293279-15 1993 These results suggest roles for increased activities of IDO, kynurenine-3-hydroxylase and kynureninase in accelerating the synthesis of QUIN, L-KYN and KYNA in conditions of brain inflammation. Quinolinic Acid 136-140 indoleamine 2,3-dioxygenase 1 Homo sapiens 56-59 31788580-2 2019 Indoleamine 2,3-dioxygenase-mediated depletion of the essential amino acid tryptophan increases susceptibility of T cells to apoptosis, while kynurenine and its downstream metabolites, such as 3-hydroxyanthranilic acid and quinolinic acid, have a direct cytotoxic effect on conventional effector T cells. Quinolinic Acid 223-238 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-27 29787958-12 2018 There was a positive correlation between QUIN and both CRP concentrations and whole blood IDO1 in MDD. Quinolinic Acid 41-45 indoleamine 2,3-dioxygenase 1 Homo sapiens 90-94 29254065-2 2018 Indoleamine 2,3-dioxygenase (IDO) is the rate limiting enzyme which leads to neurotrophic [kynurenic acid (KA)] and neurotoxic [Quinolinic acid (QUIN)] branches. Quinolinic Acid 128-143 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-27 29254065-2 2018 Indoleamine 2,3-dioxygenase (IDO) is the rate limiting enzyme which leads to neurotrophic [kynurenic acid (KA)] and neurotoxic [Quinolinic acid (QUIN)] branches. Quinolinic Acid 128-143 indoleamine 2,3-dioxygenase 1 Homo sapiens 29-32 28476779-3 2017 Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) are produced, accelerating metabolism along the kynurenine pathway and resulting in excess levels of quinolinic acid, 3-hydroxyanthranilic acid and other neurotoxic molecules. Quinolinic Acid 172-187 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-27 28476779-3 2017 Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) are produced, accelerating metabolism along the kynurenine pathway and resulting in excess levels of quinolinic acid, 3-hydroxyanthranilic acid and other neurotoxic molecules. Quinolinic Acid 172-187 indoleamine 2,3-dioxygenase 1 Homo sapiens 29-32 25547097-1 2016 Activation of the trptophan catabolite (TRYCAT) pathways by oxidative and nitrosative stress and proinflammatory cytokine-driven indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) leads to the synthesis of a number of neuroregulatory TRYCATs, such as kynurenic acid and quinolinic acid. Quinolinic Acid 290-305 indoleamine 2,3-dioxygenase 1 Homo sapiens 158-161 23669411-12 2013 Exogenous administration of IDO1 pathway metabolites kynurenine and quinolinic acid led to activation of beta-catenin and proliferation of human colon cancer cells, and increased tumor growth in mice. Quinolinic Acid 68-83 indoleamine 2,3-dioxygenase 1 Homo sapiens 28-32 26114426-7 2015 Expression of IDO-1, KMO and QPRT correlated significantly with activation of the kynurenine pathway (kynurenine:tryptophan ratio), quinolinic acid concentration and production of the monocyte derived, pro-inflammatory immune response marker: neopterin. Quinolinic Acid 132-147 indoleamine 2,3-dioxygenase 1 Homo sapiens 14-19 25066466-6 2014 IFN-alpha stimulates indoleamine-2,3 dioxygenase-1, activating the kynurenine pathway with reduced formation of the neurotransmitters serotonin and dopamine, excessive formation of the NMDA agonist quinolinic acid, and reduced formation of the NMDA antagonist kynurenic acid. Quinolinic Acid 198-213 indoleamine 2,3-dioxygenase 1 Homo sapiens 21-50 17594069-5 2007 This protective effect could to be counteracted by the production of neurotoxic metabolites of the kynurenine pathway such as quinolinic acid, which are produced upon IDO induction. Quinolinic Acid 126-141 indoleamine 2,3-dioxygenase 1 Homo sapiens 167-170 23063682-1 2012 Indoleamine dioxygenase (IDO) is a heme- containing enzyme that catalyzes the oxidation of tryptophan to N-formylkynurenine, kynurenine and the downstream quinolinic acid. Quinolinic Acid 155-170 indoleamine 2,3-dioxygenase 1 Homo sapiens 25-28 21689736-15 2011 Although the G. aurantiaca also has NadA and NadB to synthesize a quinolinic acid (a precursor of NAD(+)) via the aspartate pathway, the high activity of the G. aurantiaca IDO flanking the kynU gene suggests its IDO has a function similar to eukaryotic enzymes. Quinolinic Acid 66-81 indoleamine 2,3-dioxygenase 1 Homo sapiens 172-175 20658274-4 2011 Differences in the activation of the enzyme indoleamine 2,3-dioxygenase (IDO) and in the tryptophan-kynurenine metabolism resulting in an increased tryptophan and serotonin degradation and probably in an increased production of quinolinic acid might play a key role in major depression (MD). Quinolinic Acid 228-243 indoleamine 2,3-dioxygenase 1 Homo sapiens 73-76 19958238-8 2010 Metabolites downstream of IDO (kynurenine, quinolinic acid, kynurenic acid) were all induced in sepsis and declined in the GM-CSF group, but not in controls. Quinolinic Acid 43-58 indoleamine 2,3-dioxygenase 1 Homo sapiens 26-29 20047157-4 2010 Furthermore, the differential activation of the enzyme indoleamine 2,3-dioxygenase (IDO) and of the tryptophan/kynurenine metabolic pathway, resulting in the increased production of kynurenic acid in schizophrenia, and a possible increase in quinolinic acid in depression, also may play a key role in these diseases. Quinolinic Acid 242-257 indoleamine 2,3-dioxygenase 1 Homo sapiens 84-87 19457071-1 2009 Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting enzyme of the kynurenine pathway of tryptophan metabolism, ultimately leading to production of the excitotoxin quinolinic acid (QUIN) by monocytic cells. Quinolinic Acid 166-181 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-27 19457071-1 2009 Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting enzyme of the kynurenine pathway of tryptophan metabolism, ultimately leading to production of the excitotoxin quinolinic acid (QUIN) by monocytic cells. Quinolinic Acid 166-181 indoleamine 2,3-dioxygenase 1 Homo sapiens 29-32 19457071-1 2009 Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting enzyme of the kynurenine pathway of tryptophan metabolism, ultimately leading to production of the excitotoxin quinolinic acid (QUIN) by monocytic cells. Quinolinic Acid 183-187 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-27 19457071-1 2009 Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting enzyme of the kynurenine pathway of tryptophan metabolism, ultimately leading to production of the excitotoxin quinolinic acid (QUIN) by monocytic cells. Quinolinic Acid 183-187 indoleamine 2,3-dioxygenase 1 Homo sapiens 29-32 19918244-1 2010 Cytokine-induced activation of indoleamine 2,3-dioxygenase (IDO) catabolizes L-tryptophan (TRP) into L-kynurenine (KYN), which is metabolized to quinolinic acid (QUIN) and kynurenic acid (KA). Quinolinic Acid 145-160 indoleamine 2,3-dioxygenase 1 Homo sapiens 31-58 19918244-1 2010 Cytokine-induced activation of indoleamine 2,3-dioxygenase (IDO) catabolizes L-tryptophan (TRP) into L-kynurenine (KYN), which is metabolized to quinolinic acid (QUIN) and kynurenic acid (KA). Quinolinic Acid 145-160 indoleamine 2,3-dioxygenase 1 Homo sapiens 60-63 19918244-1 2010 Cytokine-induced activation of indoleamine 2,3-dioxygenase (IDO) catabolizes L-tryptophan (TRP) into L-kynurenine (KYN), which is metabolized to quinolinic acid (QUIN) and kynurenic acid (KA). Quinolinic Acid 162-166 indoleamine 2,3-dioxygenase 1 Homo sapiens 31-58 19918244-1 2010 Cytokine-induced activation of indoleamine 2,3-dioxygenase (IDO) catabolizes L-tryptophan (TRP) into L-kynurenine (KYN), which is metabolized to quinolinic acid (QUIN) and kynurenic acid (KA). Quinolinic Acid 162-166 indoleamine 2,3-dioxygenase 1 Homo sapiens 60-63 22084597-2 2010 It is proposed that stress induced interleukin-18 (IL-18), via interferon-gamma (IFNy) and independently, increases indoleamine 2,3-dioxygenase (IDO) and subsequent quinolinic acid (QA) in microglia. Quinolinic Acid 182-184 indoleamine 2,3-dioxygenase 1 Homo sapiens 145-148 18063923-2 2007 TRYCATs - tryptophan catabolites along the IDO pathway - such as kynurenine, kynurenic acid, xanthurenic acid, and quinolinic acid, have multiple effects, e.g. apoptotic, anti- versus pro-oxidant, neurotoxic versus neuroprotective, and anxiolytic versus anxiogenic effects. Quinolinic Acid 115-130 indoleamine 2,3-dioxygenase 1 Homo sapiens 43-46 18063923-10 2007 Following inflammation-induced IDO activation, some TRYCATs, i.e. kynurenine, kynurenic acid, and xanthurenic acid, exert a negative feedback control over IFNgamma production thus downregulating the initial inflammation, whereas an excess of quinolinic acid further aggravates the initial inflammation. Quinolinic Acid 242-257 indoleamine 2,3-dioxygenase 1 Homo sapiens 31-34 17457312-8 2007 An increased activation of IDO and its subsequent enzyme kynurenine monooxygenase by proinflammatory cytokines, moreover, leads to an enhanced production of quinolinic acid, a strong agonist of the glutamatergic N-methyl-D-aspartate receptor. Quinolinic Acid 157-172 indoleamine 2,3-dioxygenase 1 Homo sapiens 27-30 17457312-9 2007 In inflammatory states of the central nervous system, IDO is mainly activated in microglial cells, which preferentially metabolize tryptophan to the NMDA receptor agonist quinolinic acid, whereas astrocytes - counteracting this metabolism due to the lack of an enzyme of this metabolism - have been observed to be reduced in MD. Quinolinic Acid 171-186 indoleamine 2,3-dioxygenase 1 Homo sapiens 54-57 17661345-2 2007 IDO expression is induced by IFN-gamma and leads to neurotoxicity by generating quinolinic acid. Quinolinic Acid 80-95 indoleamine 2,3-dioxygenase 1 Homo sapiens 0-3